Search
Search Results
-
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study
BackgroundImmune editing, in which human leukocyte antigens (HLA) have critical roles, has been suggested to shape the landscape of human cancer....
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
BackgroundProstate cancer is a prevalent disease that urgently needs to address its treatment-related complications. By examining existing evidence...
-
Changes in the gut microbial profile during long-term androgen deprivation therapy for prostate cancer
BackgroundRecent studies have highlighted the association between androgen deprivation therapy (ADT) and the gut microbiota in prostate cancer....
-
Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study
PurposeTo assess whether androgens play a role in explaining the sex related differences in the incidence of colorectal cancer (CRC).
...
-
Shared Decision-Making and Cardiovascular Complications of Androgen Deprivation Therapy: an Educational Initiative for Oncology Team Members in Colorado, USA
Patients with prostate cancer may experience side effects of androgen deprivation therapy (ADT) such as cardiovascular (CV) complications. Oncology...
-
Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
BackgroundAlthough androgen deprivation therapy (ADT) is associated with cardiovascular risks, the extent and temporal trends of cardiovascular...
-
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer
BackgroundEvolving data suggest that men with high-risk localized prostate cancer may benefit from more potent androgen receptor inhibition in the...
-
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium
The androgen receptor (AR) is a crucial player in various aspects of male reproduction and has been associated with the development and progression...
-
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
IntroductionIn patients with metastatic hormone-sensitive prostate cancer (mHSPC) undergoing intensified androgen deprivation therapy (ADT), not...
-
Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study
BackgroundConflicting evidence exists regarding whether hormone therapy for prostate cancer is associated with neurotoxicity. Thus, we aim to...
-
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer
BackgroundIt is estimated that by 2040 there will be 1,017,712 new cases of prostate cancer worldwide. Androgen deprivation therapy (ADT) is widely...
-
Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
BackgroundTo summarize recent evidence in terms of health-related quality of life (HRQoL), functional and oncological outcomes following radical...
-
Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer
BackgroundProstate cancer is one of the most common cancers in men with notable interpatient heterogeneity. Implications of the immune...
-
NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers
BackgroundThe androgen/androgen receptor (AR)-signaling axis plays a central role in prostate cancer (PCa). Upon androgen-binding the AR dimerizes...
-
Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment
The biological function of the male hormones (androgens) is orchestrated through the activation of the androgen receptor-mediated signaling events...
-
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies....
-
Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy
BackgroundThe proposed trial is to examine the feasibility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed...
-
Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment
The biological function of the male hormones (androgens) is orchestrated through the activation of the androgen receptor-mediated signaling events...
-
Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial
BackgroundMore than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical...
-
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer
BackgroundProstate cancer is a major cause of cancer morbidity and mortality in men worldwide. Androgen deprivation therapy (ADT) has proven...
